The bisphosphonate study is an international collaboration between the NASA and JAXA space agencies to investigate the potential value of antiresorptive drugs to mitigate the well-established bone changes associated with long-duration spaceflight. Our hypothesis is that an antiresorptive drug in combination with in-flight exercise will ameliorate bone loss and hypercalcuria during long-duration spaceflight. We have completed data analysis for 7 crewmembers treated with alendronate during flight and 3 of 10 controls without treatment. We previously reported the pre/postflight changes in bone density and the pre versus in-flight changes in various biomarkers in crewmembers taking alendronate during flight. The purpose of this report is to compare these results with the 12- month follow-up data. The table below presents these data as a percentage change from baseline either immediately postflight or in-flight (biochemical markers) with a 1-year follow-up.
Update of the Bisphosphonate ISS Flight Experiment
NASA Human Research Program Investigators'' Workshop ; 2014 ; Galveston, TX, United States
2014-02-10
Conference paper
No indication
English
Update of Bisphosphonate Flight Experiment - HRP 2016
NTIS | 2016
|Ranger Telerobotic Flight Experiment Program Update
British Library Conference Proceedings | 1995
|